Primate models for cardiovascular drug research and development.
Curr Opin Investig Drugs
; 11(9): 1025-9, 2010 Sep.
Article
in En
| MEDLINE
| ID: mdl-20730697
One of the primary impediments to successful drug R&D is the frequent failure of successfully translating positive results obtained in animal models to human disease. To a large degree, this discrepancy is secondary to the substantial biological differences between species. Non-human primate models have the advantage of significant physiological, metabolic, biochemical and genetic similarity to humans. Despite this advantage, there has been a relative paucity of non-human primate models used in the study of disease states that currently underlie the most common causes of morbidity and mortality, such as chronic myocardial ischemia leading to heart failure. This review describes a primate model of heart failure that closely mimics the cardiomyopathic process observed in humans. The primary advantage of this non-human primate model is that, unlike existing heart failure models, it allows for continuous study during progressive stages of heart failure, including myocardial ischemia, progressive left ventricular remodeling and end-stage congestive heart failure. In addition to this model of heart failure, other non-human primate models for cardiovascular drug R&D are also reviewed.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Primates
/
Cardiovascular Agents
/
Cardiovascular Diseases
/
Disease Models, Animal
/
Heart Failure
Type of study:
Etiology_studies
Limits:
Animals
Language:
En
Journal:
Curr Opin Investig Drugs
Journal subject:
TERAPIA POR MEDICAMENTOS
Year:
2010
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom